Ocugen Signs OCU400 Licensing Agreement with Roots Pharma
MALVERN, Pa., July 13, 2026 Ocugen announced the signing of a binding term sheet with Roots Pharmaceutical and its...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
MALVERN, Pa., July 13, 2026 Ocugen announced the signing of a binding term sheet with Roots Pharmaceutical and its...
DALLAS, May 11, 2026 Nanoscope Therapeutics announced multiple scientific presentations at the American Society of Gene and Cell Therapy...
Research Triangle Park, N.C. | January 27, 2026 — Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on inherited...
Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...
